Treatment with a tumor necrosis factor (TNF) inhibitor among patients with rheumatic and autoimmune diseases failed to decrease their risk of fractures, a retrospective study found.

For patients with rheumatoid arthritis, the hazard ratio for fracture on a combined endpoint that included hip, humerus, radius/ulna, or pelvis was a nonsignificant 1.17 (95% CI 0.91-1.51) compared with patients receiving conventional treatments, according to Marie R. Griffin, MD, of Vanderbilt University in Nashville, and colleagues.

Similarly, the risks were not elevated for patients with inflammatory bowel disease (HR 1.49, 95% CI 0.72-3.11) or for a combined group of patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis (HR 0.92, 95% CI 0.47-1.82), the researchers reported in the July Arthritis Care & Research.